Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
diabetic nephropathy model
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "diabetic nephropathy model" in MCE Product Catalog:
3
Benazepril (CGS14824A) hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril hydrochloride inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. In addition, Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria. Benazepril hydrochloride can be used in the study of hypertension, heart failure and diabetic nephropathy .
3
製品番号: HY-P990540
別名: CSL346; Reflocibart
Target:
研究分野:
製品番号: HY-B1451
CAS 番号: 89396-94-1
別名: TA-6366
Imidapril hydrochloride (TA-6366) is an orally active dual inhibitor of angiotensin-converting enzyme (ACE) and MMP-9. Imidapril hydrochloride inhibits lipopolysaccharide-induced phosphorylation of c-Jun, MKK4 and JNK in monocytes, and downregulates the production of specific inflammatory factors such as TNF-α and IP-10, thereby exerting anti-inflammatory activity. Imidapril hydrochloride also effectively ameliorates mesangial expansion and reduces urinary albumin excretion by inhibiting angiotensin AngII production, lowering glomerular pressure and oxidative stress, thus delaying disease progression. Imidapril hydrochloride can also directly bind to the active site of MMP-9 to inhibit gelatinase activity, and suppress the enlargement of cerebral aneurysms without altering systemic blood pressure. Imidapril hydrochloride is widely applicable to related studies on autoimmune glomerulonephritis, diabetic nephropathy, cerebral aneurysms and other conditions .
別名: Ro 67-0565; SPP-301
Target:
Avosentan (Ro 67-0565; SPP-301) is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure .
製品番号: HY-113089
CAS 番号: 17105-15-6
別名: H-Glu(H-Lys-OH)-OH; γ-Glu-ε-Lys
Target:
製品番号: HY-113089A
純度: 98.55%
別名: H-Glu(H-Lys-OH)-OH TFA; γ-Glu-ε-Lys TFA
Target:
製品番号: HY-113089AR
別名: H-Glu(H-Lys-OH)-OH TFA (Standard); γ-Glu-ε-Lys TFA (Standard)
Category:
製品番号: HY-14923
CAS 番号: 473289-62-2
別名: AVE 7688
研究分野:
Ilepatril, a dual inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase, has inhibitory effects in the type 2 diabetic nephropathy model in obese Zucker diabetic fatty (ZDF) rats. Ilepatril significantly reduced albuminuria in a dose-dependent manner and may be a strategy distinct from metabolic control to inhibit type 2 diabetic nephropathy .
製品番号: HY-100819
CAS 番号: 1365266-79-0
Target:
研究分野:
RO5234444 is an orally active CCR2 antagonist, with IC50s of 22nM for human CCR2 and 161 nM for mouse CCR2. RO5234444 alleviates glomerulosclerosis, reduces albuminuria, and significantly improves the glomerular filtration rate (GFR) in the uninephrectomized (1K) type 2 diabetic db/db mouse model. RO5234444 can be used for the study of type 2 diabetic nephropathy .
製品番号: HY-123409
CAS 番号: 704881-43-6
Target:
研究分野:
Nicousamide is a potent inhibitor of TGF-β RII phosphorylation. Nicousamide can be used to study renal fibrosis in animal models of diabetic nephropathy .
製品番号: HY-15195R
CAS 番号: 290815-26-8
別名: Ro 67-0565 (Standard); SPP-301 (Standard)
Avosentan (Standard) is the analytical standard of Avosentan (HY-15195). This product is intended for research and analytical applications. Avosentan is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction, and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure.
製品番号: HY-N19615
CAS 番号: 134859-90-8
製品番号: HY-P992410
Target:
研究分野:
製品番号: HY-N17737
CAS 番号: 1487423-58-4
製品番号: HY-118945
CAS 番号: 194928-55-7
FR191413 is a selective bradykinin B2 receptor agonist that stimulates prostaglandin E2 production in WI-38 cells and activates BK B2 receptor-mediated pathways such as vasodilation and organ protection. FR191413 competitively binds to [ 3H]-BK in guinea pig ileum (GPI) membranes and CHO cells transfected with the human BK B2 receptor, with IC50 values of 20.0 nM and 2.60 nM, respectively. FR191413 can be used in research related to cardiovascular diseases and diabetes, including hypertension, myocardial hypertrophy, myocardial infarction, arrhythmias, and diabetic nephropathy .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
